Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
554 results about "Uterine fibroids" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A non-cancerous tumors in the uterus.
Method, system and device for tissue removal
A method and device for tissue removal. The device may be used to remove uterine fibroids and other abnormal gynecological tissue. According to one embodiment, the device includes a housing, an outer tube, and an inner tube. The outer tube is fixed to the housing and includes a side window proximate to its distal end. The side window may have sloped proximal and distal ends. The inner tube has a distal end positioned within the outer tube, the distal end being adapted to rotate and, at the same time, to move back and forth past the side window, with the rotational and translational movement of the inner tube being independently controllable. The distal end of the inner tube may have an external bevel. Suction is applied to the proximal end of the inner tube to draw tissue into the side window and to remove resected tissue through the inner tube.
Owner:HOLOGIC INC
Ultrasound-based procedure for uterine medical treatment
InactiveUS20050256405A1Short treatment timeStopUltrasonic/sonic/infrasonic diagnosticsChiropractic devicesVascular supplyUterine bleeding
A first method for ultrasound uterine medical treatment includes obtaining an end effector having an ultrasound medical-treatment transducer assembly, identifying a blood vessel which supplies blood to a portion of the uterus, and medically treating the blood vessel with ultrasound from the transducer assembly to substantially seal the blood vessel to substantially stop the supply of blood from the blood vessel to the portion of the uterus. In one example, shrinkage of a uterine fibroid is accomplished through use of the end effector endoscopically inserted into the uterus. A second method for ultrasound uterine medical treatment includes endoscopically inserting the end effector into the uterus and medically treating the endometrium lining with ultrasound from the transducer assembly to ablate a desired thickness of at least a portion of the endometrium lining to substantially stop abnormal uterine bleeding from the endometrium lining.
Owner:ETHICON ENDO SURGERY INC
Image guided high intensity focused ultrasound device for therapy in obstetrics and gynecology
InactiveUS20050203399A1Spread the wordNegatively affectedUltrasound therapyOrgan movement/changes detectionCervixUterus
A frame ensures that the alignment between a high intensity focused ultrasound (HIFU) transducer designed for vaginal use and a commercially available ultrasound image probe is maintained, so that the HIFU focus remains in the image plane during HIFU therapy. A water-filled membrane placed between the HIFU transducer and the treatment site provides acoustic coupling. The coupling is evaluated to determine whether any air bubbles exist at the coupling interface, which might degrade the therapy provided by the HIFU transducer. HIFU lesions on tissue appear as hyperechoic spots on the ultrasound image in real time during application of HIFU therapy. Ergonomic testing in humans has demonstrated clear visualization of the HIFU transducer relative to the uterus and showed the potential for the HIFU transducer to treat fibroids from the cervix to the fundus through the width of the uterus.
Owner:UNIV OF WASHINGTON
Echogenic needle for transvaginal ultrasound directed reduction of uterine fibroids and an associated method
InactiveUS6936048B2Increase awarenessImprove gripUltrasonic/sonic/infrasonic diagnosticsSurgical needlesVascular supplyRadio frequency
The invention is a transvaginal ultrasound probe having an attached echogenic needle that is useful in the treatment of uterine fibroids. The echogenic needle has an echogenic surface near its tip that allows the physician to visualize its location using ultrasound imaging. In one embodiment, the needle has an active electrode at its distal end. The active electrode supplies radio frequency energy to a fibroids causing necrosis of the targeted fibroid or by destroying the fibroid's vascular supply. The radio frequency needle preferably has a safety device that shuts-off energy if the needle punctures the uterine wall. In a second embodiment, the needle has a cryogen supply tube and cryogen supply. This embodiment destroys fibroid tissue by freezing it or its vascular supply when the tissue comes in contact with the needle's frozen distal end. The invention further includes the method of using the ultrasound probe with the attached needle.
Owner:GYNESONICS
Surgical fluid management systems and methods
A surgical fluid management system delivers fluid for distending a uterine cavity to allow cutting and extraction of uterine fibroid tissue, polyps and other abnormal uterine tissue. The system comprises a fluid source, fluid deliver lines, one or more pumps, and a filter for re-circulating the distension fluid between the source and the uterine cavity. A controller can monitor fluid retention by the patient.
Owner:BOSTON SCI SCIMED INC
Apparatus and method for thermal ablation of uterine fibroids
InactiveUS20070088247A1Improve mobilityProtection from damageCannulasEndoscopesThermal insulationCervix
The present invention relates to apparatus and methods for thermally ablating uterine fibroids. More particularly, the present invention relates to a conduit having a plurality of channels for delivering a plurality of thermal ablation probes to an organic target such as a uterine fibroid, the probes being delivered in such configuration and orientation as to enable efficient and thorough ablation of the fibroid. In a preferred embodiment, the conduit is formed as a sleeve having a large central lumen sized to accommodate a hysteroscope, channels sized to accommodate cryoprobes are used as thermal ablation probes, and comprises thermal insulation materials serving to protect the cervix from damage by cold. The present invention further relates to bent cryoprobes usable in conjunction with such a conduit and designed to exit therefrom in a desired configuration useful for ablating a large fibroid.
Owner:GALIL MEDICAL
Echogenic needle for transvaginal ultrasound directed reduction of uterine fibroids and an associated method
InactiveUS20050228288A1Increase awarenessEasily grip and manipulateUltrasonic/sonic/infrasonic diagnosticsSurgical needlesVascular supplyRadio frequency
The invention is a transvaginal ultrasound probe having an attached echogenic needle that is useful in the treatment of uterine fibroids. The echogenic needle has an echogenic surface near its tip that allows the physician to visualize its location using ultrasound imaging. In one embodiment, the needle has an active electrode at its distal end. The active electrode supplies radio frequency energy to a fibroids causing necrosis of the targeted fibroid or by destroying the fibroid's vascular supply. The radio frequency needle preferably has a safety device that shuts-off energy if the needle punctures the uterine wall. In a second embodiment, the needle has a cryogen supply tube and cryogen supply. This embodiment destroys fibroid tissue by freezing it or its vascular supply when the tissue comes in contact with the needle's frozen distal end. The invention further includes the method of using the ultrasound probe with the attached needle.
Owner:CHARLOTTE MECKLENBURG HOSPITAL AUTHORITY
Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
The present invention relates, inter alia, to compounds having the general formula: in which: R1 is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —NC4H8, —NC5H10, —NC4H8O, —CHO, —CH(OH)CH3, —C(O)CH3, —O(CH2)2N(CH3)2, and —O(CH2)2NC5H10; R2 is a member selected from the group consisting of hydrogen, halogen, alkyl, acyl, hydroxy, alkoxy (e.g., methoxy, ethoxy, vinyloxy, ethynyloxy, cyclopropyloxy, etc.), acyloxy (e.g., acetoxy, glycinate, etc.), alkylcarbonate, cypionyloxy, S-alkyl, —SCN, S-acyl and —OC(O)R6, wherein R6 is a functional group including, but not limited to, alkyl (e.g., methyl, ethyl, etc.), alkoxy ester (e.g., —CH2OCH3) and alkoxy (—OCH3); R3 is a member selected from the group consisting of alkyl, hydroxy, alkoxy and acyloxy; R4 is a member selected from the group consisting of hydrogen and alkyl; and X is a member selected from the group consisting of ═O and ═N—OR5, wherein R5 is a member selected from the group consisting of hydrogen and alkyl.In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat meningiomas; to treat uterine leiomyomas; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce cervical ripening; to induce labor; and for contraception.
Owner:HEALTH & HUMAN SERVICES THE GOVERNMENT OF THE US SEC THE DEPT OF
Method for treatment of uterine fibroid tumors
InactiveUS20060251581A1Improve delivery efficiencyMinimize adverse effectsUltrasonic/sonic/infrasonic diagnosticsPowder deliverySemi solidViscosity
Various injectable or insertable uterine fibroid treatment formulations are provided, which comprise a uterine fibroid treatment agent in an amount effective to cause shrinkage or elimination of uterine fibroids. The injectable or insertable formulations are typically solids, semi-solids or high-viscosity fluids. Other aspects of the invention are directed to systems and methods for treatment of uterine fibroids.
Owner:SCI MED LIFE SYST
21-substituted progesterone derivatives as new antiprogestational agents
A compound having the general formula: in which: R1 is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —CHO, —COCH3 and —CHOHCH3; R2 is a member selected from the group consisting of halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkyl carbonate, cypionyloxy, S-alkyl and S-acyl; R3 is a member selected from the group consisting of alkyl, hydroxy, alkoxy and acyloxy; R4 is a member selected from the group consisting of hydrogen and alkyl; and X is a member selected from the group consisting of ═O and ═N—OR5, wherein R5 is a member selected from the group consisting of hydrogen and alkyl.In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; and for contraception.
Owner:DEPT OF HEALTH & HUMAN SERVICES THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SEC OF THE
Gel injection treatment of breast, fibroids & endometrial ablation
A method and apparatus for treatment of diseases of a breast, fallopian tube and female reproductive organs by injecting / delivering a treatment substance / chemo-gel, directly into the target tissue of the body organ, and thereby leaving the remaining body organs relatively unaffected. Specific formulations and composition of treatment substances are provided. The typical treatment substance / chemo-gel formulations contain at least two principle components including an active treatment (therapy) substance, and an inactive binding (carrier) substance for thickening the treatment substance. Specific substance formulations are provided, including a range of recommended dosage levels for optimum treatment of a specific disease of a female reproductive organ. Injection / delivery apparatus and methods, and apparatus for guiding its placement are also provided.
Owner:PRO SURG
p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth
InactiveUS20130149314A1Reduced cell capacityOrganic active ingredientsBiocideDiseaseMesenchymal stem cell
Provided are novel methods and compositions for the diagnosis, prognosis and treatment of leiomyomas, in particular uterine leiomyoma (UL). In addition, methods of identifying anti-tumor agents are described. Furthermore, novel methods and compositions are provided for the treatment of diseases characterized by an aberrant growth of mesenchymal stem cells and their descendants and for the treatment of obesity are disclosed.
Owner:UNIV OF BREMEN
Minimally Invasive Methods and Apparatus for Accessing and Ligating Uterine Arteries with Sutures
InactiveUS20060276808A1Easy accessShorten surgical time and traumaSuture equipmentsSurgical needlesVeinLigament structure
Surgical procedures, tools, and kits particularly suited to effect uterine artery ligation in a minimally invasive manner to treat uterine fibroids or other conditions of the uterus are disclosed. An incision through the fornix is made to access the uterine arteries supported by the cardinal and uterosacral ligaments. A distal end of one or more sutures is passed around each uterine artery and a portion of the ligament supporting and enclosing the uterine artery, wherein the portion may include a uterine vein. The passage is effected by directing a suture distal end along a first side of the portion of the ligament beyond to the fornix incision, then through the ligament, and then back proximally along the second ligament side toward the fornix incision.
Owner:AMS RES CORP
Methods and systems for ablating tissue
InactiveUS20080045890A1Improve side effectsLess damage to the heart's electrical functionsBalloon catheterMedical devicesAbnormal tissue growthHypertrophic cardiomyopathy
Methods and systems for treating patients requiring tissue ablation for volumetric tissue reduction rely on the injection of ethanol and other tissue-ablating agents into the perivascular space surrounding body lumens, particularly blood vessels or vessels of the alimentary canal, reproductive system and urinary tract. Injection of tissue-ablating agents is intended treat conditions such as hypertrophic cardiomyopathy, benign and malignant tumors, benign prostatic hyperplasia, and uterine fibroids, for example. Injection may be achieved using intravascular catheters which advance needles radially outward from a body vessel lumen or by transmyocardial injection from an epicardial or endocardial surface of the heart.
Owner:MERCATOR MEDSYST
Uterine artery occlusion device with cervical receptacle
InactiveUS20050113852A1Simpler and more readily usedSimpler and more readily and removedBlood flow measurement devicesFemale contraceptivesUterine DisorderDisease
The invention is directed to an intravaginal uterine artery occlusion device for treating uterine disorders such as fibroids, dysfunctional uterine bleeding, postpartum hemorrhage and the like. A occlusion device has a cervical receptacle or cap with an open distal end for receiving the patient's uterine cervix and an elongated shaft having a distal end secured to the closed proximal end of the cervical receptacle and an inner lumen extending to the distal end of the elongated shaft. The patient's uterine cervix is held within the interior of the receptacle by the application of a vacuum to the interior of the receptacle through the inner lumen of the shaft or otherwise, while the leading edge(s) of the cervical receptacle press against the patient's vaginal fornix to occlude an underlying or adjacent uterine artery. At least one blood flow sensor may be provided on the leading edge of the receptacle to aid in locating a uterine artery and to monitor blood flow through the located uterine artery.
Owner:VASCULAR CONTROL SYST
Method of preventing or treating benign gynaecological disorders
ActiveUS8071576B2Few side-effectsLow recurrence rateBiocideOrganic active ingredientsDiseaseGynecological disorders
The present invention relates to a method of preventing or treating benign estrogen sensitive gynecological disorders in a female mammal, wherein the method comprises the administration to said female mammal of a combination of progestogen and androgen in an amount that is therapeutically effective to prevent or reduce the symptoms of these disorders. The present method is particularly suitable for preventing or treating disorders selected from the group consisting of endrometriosis, adenomyosis, uterine fibroids, dysmenorrhoea, menorrhagia and metrorrhagia. Another aspect of the invention relates to a pharmaceutical kit comprising a plurality of oral dosage units which comprise a progestogen in an amount equivalent to 3-500 μg levonorgestrel and either 5 to 250 mg dehydroepiandrosterone or 1 to 50 mg testosterone undecanoate.
Owner:PANTARHEI BIOSCI
Intrauterine system
ActiveUS8568374B2Control releaseSuppositories deliverySkeletal disorderOsteopoikilosisUterine bleeding
An intrauterine system is disclosed for use in the treatment of dysfunctional uterine bleeding; menorraghia; dysmenorrhoea; endometriosis; uterine fibroids; climacteric complaints; osteoporosis; and urogenital atrophy. The system is formed by a frame defining an interior space for receipt of a deposit of a therapeutically effective dose of a biologically active compound. The frame has an open structure allowing access to a substantial part of an outer surface of the deposit, and the deposit has a rate controlling structure that controls a rate of release of the compound within the uterus. One or more retention elements are provided on the frame for retaining the frame within the uterus of a female mammal.
Owner:NV ORGANON
Use of an mTOR inhibitor in treatment of uterine leiomyoma
Owner:WYETH LLC
Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and / or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and / or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.
Owner:ORTHO MCNEIL PHARM INC
Image guided high intensity focused ultrasound device for therapy in obstetrics and gynecology
InactiveUS7520856B2Spread the wordNegatively affectedUltrasound therapyOrgan movement/changes detectionCervixUterus
A frame ensures that the alignment between a high intensity focused ultrasound (HIFU) transducer designed for vaginal use and a commercially available ultrasound image probe is maintained, so that the HIFU focus remains in the image plane during HIFU therapy. A water-filled membrane placed between the HIFU transducer and the treatment site provides acoustic coupling. The coupling is evaluated to determine whether any air bubbles exist at the coupling interface, which might degrade the therapy provided by the HIFU transducer. HIFU lesions on tissue appear as hyperechoic spots on the ultrasound image in real time during application of HIFU therapy. Ergonomic testing in humans has demonstrated clear visualization of the HIFU transducer relative to the uterus and showed the potential for the HIFU transducer to treat fibroids from the cervix to the fundus through the width of the uterus.
Owner:UNIV OF WASHINGTON
Methods for minimally-invasive, non-permanent occlusion of a uterine artery
Non-permanent occlusion of the uterine arteries is sufficient to cause the demise of uterine myomata without unnecessarily exposing other tissues and anatomical structures to hypoxia attendant to prior permanent occlusion techniques. A therapeutically effective transient time of occlusion of a uterine artery to treat uterine fibroid tumors is from 1 hours to 24 hours, and preferably is at least about 4 hours. A therapeutically effective temporary time of occlusion of a uterine artery to treat uterine fibroid tumors is from 1 day (24 hours) to 7 days (168 hours), and preferably is about 4 days (96 hours). By invaginating the tissues of the vaginal wall up to or around a uterine artery, collapse of the uterine artery can be achieved without penetrating tissue of the patient.
Owner:VASCULAR CONTROL SYST
Estrogen receptor modulators
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
Owner:MERCK SHARP & DOHME CORP
Selective estrogen receptor modulators
InactiveUS7157604B2Urea derivatives preparationBiocideHormone Receptor ModulatorsPercent Diameter Stenosis
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
Owner:MERCK & CO INC
Method for Treating Uterine Fibroids
ActiveUS20090192130A1Reduce and stop bleedingSmall sizeOrganic active ingredientsPill deliveryMetaboliteUterine fibroids
The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and / or for reducing the size of uterine fibroids.
Owner:UNITED STATES OF AMERICA +1
Quinoline derivatives, their production and use
The present compounds are intermediates for the preparation of quinoline derivatives and compositions having gonadotropin-releasing hormone antagonistic activity useful as propylactics or therapeutic agent for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer (e.g. prostatic cancer, uterine or cervical cancer, breast cancer, pituitary adenoma), benign prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, polycystic ovary syndrome and acne vulgaris; are effective as a fertility controlling agent in both sexes (e.g. a pregnancy controlling agent and a menstrual cycle controlling agent); can be used as a male or female contraceptive, as an ovulation-inducing agent; can be used as an infertility treating agent by using a rebound effect owing to a stoppage of administration thereof; and are useful for modulating estrous cycles in animals in the field of animal husbandry, as agents for improving the quality of edible meat or promoting the growth of animals, and as agents for promoting spawning in fish.
Owner:TAKEDA PHARMA CO LTD
Chinese medicinal preparation for treating breast diseases and uterine fibroid and preparation method thereof
InactiveCN102727832AGood treatment effectHigh cure rateAntineoplastic agentsSexual disorderDiseaseMyrrh
The invention discloses a Chinese medicinal preparation for treating breast diseases and uterine fibroid and a preparation method thereof. The Chinese medicinal preparation is prepared by extracting and mixing the following raw materials in percentage by weight: 8 to 15 percent of Chinese thorowax root, 4 to 6 percent of turmeric root-tuber, 3 to 6 percent of pangolin, 4 to 6 percent of nutgrass galingale rhizome, 3 to 5 percent of thunbery fritillary bulb, 3 to 5 percent of snake gourd fruit, 3 to 4 percent of hemlock parsley, 3 to 5 percent of suberect spatholobus stem, 2 to 4 percent of red-rooted salvia root, 2 to 3 percent of common burreed rhizome, 2 to 3 percent of curcuma zedoary, 2 to 3 percent of frankincense, 2 to 3 percent of myrrh, 3 to 5 percent of rhizoma corydalis, 3 to 5 percent of turtle shell, 2 to 4 percent of spina gleditsiae, 2 to 3 percent of semen litchi, 5 to 6 percent of selfheal, 3 to 6 percent of Astragalus root, 2 to 4 percent of angelica, 2 to 3 percent of Atractylis ovate, 2 to 3 percent of white peony root, 2 to 3 percent of poria, and 2 to 3 percent liquorice. The Chinese medicinal preparation can be used for treating patients with hyperplasia of mammary glands, mamstitis or hysteromyoma, and has high clinical cure rate and good healing effect.
Owner:王焕江
Structural modification of 19-norprogesterone I: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
InactiveUS20050143365A1Organic active ingredientsDrug compositionsAbnormal tissue growthInducing labor
Owner:UNITED STATES OF AMERICA
Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
![Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/48b1a46e-06bc-4b13-9c75-4a9a0b69d2de/US07399767-20080715-C00001.png "Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors")
![Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/48b1a46e-06bc-4b13-9c75-4a9a0b69d2de/US07399767-20080715-C00002.png "Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors")
![Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/48b1a46e-06bc-4b13-9c75-4a9a0b69d2de/US07399767-20080715-C00003.png "Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors")
Owner:JANSSEN PHARMA NV
Ablation method
A method of ablating a uterine fibroid using a particular trocar is disclosed. The trocar comprises a plurality of ablation stylets mounted for movement from within the trocar to positions extending from the trocar. The trocar is adjustable to assume a plurality of configurations, each of the configurations having the stylets extended to a different extent from the trocar. A region to be ablated is imaged. The region may correspond to all or a portion of a uterine fibroid. The size of the region to be ablated is noted. The size of the region to be ablated is compared to a matrix of known ablation regions, each of the known ablation regions being associated with one of the configurations of the particular trocar, and each of the known ablation regions being associated with a position of the trocar relative to the known ablation region. The region to be ablated is associated with a most nearly matching known ablation region by comparison of the region to be ablated to the known ablation regions. A trocar of the design of the particular trocar is inserted into the uterine fibroid at a position, with respect to the region to be ablated, which more closely matches the position of the particular trocar with respect to the known ablation region. The stylets are deployed from the trocar to an extent corresponding to the configuration associated with the most nearly matching known ablation region.
Owner:ACESSA HEALTH INC
Method and device for canulation and occlusion of uterine arteries
A method for treating a uterine fibroid comprises forming an incision in a vaginal fornix to expose a first blood vessel supplying the fibroid, forming an opening in the first blood vessel and inserting an introducer into the first blood vessel via the opening in combination with the steps of advancing a catheter to a desired position within the first blood vessel via the introducer and introducing an occlusive agent into the first blood vessel through the catheter to block blood flow through the first blood vessel. A device for treating uterine fibroids comprises an elongated sheath sized for insertion into uterine arteries via an incision in the vaginal fornix, the sheath including a sheath lumen extending from a first sheath opening formed in a proximal end of the sheath to a second sheath opening formed in a distal end of the sheath and a body a distal end of which is connected to the proximal end of the sheath, the body including a body lumen extending therethrough from a first body opening at a proximal end of the body and a second body opening at the distal end thereof, the second body lumen communicating with the sheath lumen in combination with a hemostatic valve controlling the flow of blood through the body lumen.
Owner:BOSTON SCI SCIMED INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com